The correlation between coagulation test and albumin with antithrombin III in Dengue hemorrhagic fever.

AIM: To analyse the correlation between coagulation tests (PT APTT fibrinogen, D-dimer) and albumin with AT-II in DHF as well to find the formula to calculate AT-III with the parameter of coagulation tests and albumin. METHODS: A descriptive-correlative cross sectional study was conducted to 49 patients with DHF consisted of DHF I(17), DHF (19), DHF III (6) and DHF IV (7). The diagnosis of DHF is based on WHO criteria 1997. The laboratory examinations were coagulation tests (PT, APT, fibrinogen and D-dimer), antithrombin III and albumin, performed when the fever subside and the platelets reached the lowest count(4(th) - 6(th) day). RESULTS: A significant correlation was found between PT and AT-III (r= -0.631; p=0.000), between D-dimer and AT-III (r= -0.337; p=0.021) and between albumin and AT-III (r= 0.291; p-0.045). In multiple linier regression analysis(backward), AT-III can be calculated with the formula, accuracy 68.3%. CONCLUSIONS: PT and D-dimer were correlated negatively with AT-III, however albumin was correlated positively with AT-III. PT, D-dimer and AT-III were correlated with the grading severity of the DHF. In this study, AT-III can be calculated with the formula, accuracy 68.3%.

Antithrombin III activity in cerebrovascular accidents.

Cerebrovascular accidents are commonly due to occlusive or haemorrhagic lesions. The present prospective study was planned to find out role of antithrombin in possible etiopathological process, which might predispose an individual for stroke. METHOD: Biological activity of antithrombin III was done by the method as described by Innerfield et al (1976). Immunological estimation of an antithrombin III was done by single radial immunodiffusion by the technique of Mancini et al modified by Fahey and Mckelvey. RESULTS: The biological and immunological activity of antithrombin III was measured in 98 patient of occlusive and 56 patients of haemorrhagic strokes. Significant depression in biological as well as immunological activity (p<0.001) was observed in occlusive stroke. In haemorrhagic stroke both, biological and immunological activity was increased. In follow up study, there was progressive normalization of both, biological as well as of immunological activity in both group. CONCLUSION: Decrease of antithrombin III in occlusive and increase in haemorrhagic stroke indicates that these changes have at least an additive role in the pathogenesis of stroke.

Thrombin antithrombin III [TAT] in patients with acute myocardial infarction

This study was conducted on 20 patients with acute myocardial infarction [AMI] and 20 healthy persons, as a control group, they were clinically free from any systemic disease. It was found that the mean TAT level was highly significantly increased in patients with AMI when compared to healthy persons and can be used as an additional criteria for diagnosis of AMI. There was a positive correlation between the mean level of TAT and the extent of infarction. After administration of thrombolytic therapy there was another elevation in the mean TAT level which may indicate reperfusion of the infarct area. Also, after administration of heparin, here was another elevation which may be due to the fact that heparin accelerate the reaction between thrombin and antithrombin III

Trombosis y neoplasia / Thrombosis and neoplasia

Se describe la relación entre distintos eventos trombóticos y la coexistencia de cáncer oculto o conocido. Se analizan los fenómenos protrombóticos involucrados en este tipo de pacientes y las alteraciones que se producen en el sistema de coagulación y de anticoagulación. Se analiza la ayuda del laboratorio y se comenta el tratamiento específico del episodio de trombosis en los cancerosos

Antithrombin III in liver disorders.

Biological and immunological antithrombin III was studied in 26 patients of viral hepatitis including 6 with encephalopathy, and in 11 patients with cirrhosis of liver. There was a significant reduction in both biological and immunological activity of antithrombin III in all the groups of liver disorders studied. There was a good correlation between biological and immunological activity of antithrombin III (P less than 0.05). Further, there was a significant inverse correlation between immunological activity of antithrombin III and SGOT/SGPT (P less than 0.01) as well as serum bilirubin (P less than 0.001), signifying the prognostic value of antithrombin III in hepatitis. Biological activity on the other hand did not show any relation with the hepatic enzymes or bilirubin elevation. The antithrombin III levels appeared to decline in direct proportion to the degree of hepatic necrosis, probably due to reduced synthesis.

Tromboembolismo inexplicado / Thromboembolism unexplained

Los pacientes con alteraciones tromboembolicas recidivantes o infrecuentes pueden tener anormalidades en el proceso de regulacion de la hemostasis, como consecuencia de deficiencias hereditarias o adquiridas de antitrombina III, proteina C o proteina S. En estos casos el medico requiere de suficientes conocimientos del proceso de coagulacion y suspicacia a fin de establecer el diagnostico. Mediante el tratamiento anticoagulante apropiado y oportuno se puede salvar la vida de estos pacientes

Antitrombina: III. Algunas consideraciones generales / Antithrombin: III. Some general considerations

Se plantea que la ATIII es el principal inhibidor fisiológico de la trombina en el plasma, además inhibe a los factores Xa, IXa, XIa, XIIa, a plasmina y la calicreína plasmática. Se informa que la ATIII es una glicoproteína de peso molecular entre 58000 y 67000 daltons, compuesta por una cadena polipeptídica. Se indica que la capacidad inhibitoria de la ATIII es acelerada en presencia de heparina. Se plantea que existen varias hipótesis acerca del mecanismo de reacción sustentadas por hechos experimentales. Se señala que hay una correlación entre los niveles reducidos de ATIII y la predisposición a manifestaciones trombóticas, lo que es una evidencia de la importancia de su función regulatoria en el mecanismo hemostático